Anixa Biosciences Inc. (ANIX) intrinsic value & 10-year financials
Anixa Biosciences Inc. (ANIX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.67
- Market cap
- $86.7K
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -4.4%
- ROIC (10-yr avg)
- -172.5%
- Free cash flow (FY2025)
- —
ANIX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$10.9M | -$0.34 | — | — | -66.2% |
| FY2024 | $210.0K | -$12.6M | -$0.39 | — | -6586.2% | -59.1% |
| FY2023 | $210.0K | -$9.8M | $0.32 | — | -5243.3% | -48.6% |
| FY2022 | — | -$13.6M | $0.45 | — | — | -116.2% |
| FY2021 | $512.5K | -$13.0M | — | — | -2563.1% | -198.4% |
| FY2020 | — | -$10.0M | — | -$6.2M | — | -143.2% |
| FY2019 | $250.0K | -$11.6M | — | -$4.9M | -4756.0% | -218.3% |
| FY2018 | $1.1M | -$14.0M | — | -$4.3M | -1284.4% | -209.6% |
| FY2017 | $362.5K | -$7.0M | — | -$3.8M | -1676.0% | -157.5% |
| FY2016 | $300.0K | -$5.0M | — | -$3.5M | -1503.0% | -508.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Anixa Biosciences Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Anixa Biosciences Inc has historically struggled to out-earn its cost of capital, averaging just -44.6% ROIC.
Anixa Biosciences Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Anixa Biosciences Inc is modeled at -4.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.06 per share.